Middle East & Africa Malaria Treatment Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Treatment (Prescription Medications, Vaccines, Diagnostic Tests, and Others), Drug Type (Branded and Generic), Route of Administration (Oral and Pa

Middle East & Africa Malaria Treatment Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Treatment (Prescription Medications, Vaccines, Diagnostic Tests, and Others), Drug Type (Branded and Generic), Route of Administration (Oral and Parenteral & Intravenous), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and End User (Hospitals, Specialty Clinics, Homecare, and Others)

The MEA malaria treatment market is expected to grow from US$ 51.35 million in 2022 to US$ 63.02 million by 2028. It is estimated to grow at a CAGR of 3.5% from 2022 to 2028.

Increasing Prevalence of Malaria is Fueling the MEA Malaria Treatment Market

According to the World Health Organization (WHO), malaria is an acute febrile illness caused by plasmodium parasites, which spread through the bites of infected female Anopheles mosquitoes. Malaria is caused by five parasite species in humans, and two of these species—Plasmodium falciparum and P. vivax—pose the greatest threat. P. falciparum is the deadliest malarial parasite, and it is the most widespread one on the African continent. The WHO’s African region continues to account for a disproportionately high share of the global burden of malaria. In 2020, 95% of the global cases of malaria and 96% of deaths were reported in Africa; ~80% of the total deaths caused by malaria are reported in children below five years of age. Four African countries—Nigeria (31.9%), the Democratic Republic of the Congo (13.2%), the United Republic of Tanzania (4.1%), and Mozambique (3.8%)—accounted for nearly half of all malaria-related deaths reported worldwide. According to the LANCET Regional Health 2020, the burden of malaria is the highest in African countries (95%); P. falciparum is the cause of the brunt of mortality in children younger than 5 (∼ 77%) across the world, and in African countries, this species accounts for ∼ 96% of total mortalities caused among children by malaria. The rising prevalence of malaria boosts the MEA malaria treatment market t growth.

MEA Malaria Treatment Market Overview

The MEA malaria treatment market is categorized into the UAE, Saudi Arabia, South Africa, Nigeria, The Democratic Republic of Congo, the United Republic of Tanzania, Mozambique, Uganda, Ghana, Burkino Faso, Kenya, Zambia, and the Rest of MEA. In 2021, Saudi Arabia was the largest market for malaria treatment in the region. In 2020, Saudi Arabia witnessed 3,367 people infected with malaria. Additionally, 3,304 cases of malaria (98%) were recorded among teenagers aged 15 and above. The current elimination or treatment strategies in Saudi Arabia focus mainly on targeting the high-risk areas for sustained preventative measures, including management of infection through rapid confirmed diagnosis and treatment. Individual case follow-up and reactive surveillance with appropriate treatment and vector control and active case detection at borders with screening and treatment. Current malaria treatments are also based on the use of artemisinin-based combinations. In Saudi Arabia, the combination of pyrimethamine/sulfadoxine/artesunate is the first line of treatment for uncomplicated malaria, while lumefantrine/artemether (Coartem) is used as a second option. The treatment for severe malaria rests on the use of quinine or artesunate.

MEA Malaria Treatment Market Revenue and Forecast to 2028 (US$ Million)

MEA Malaria Treatment Market Segmentation

The MEA malaria treatment market is segmented based on treatment, drug type, route of administration, distribution channel, end user, and country.

Based on treatment, the MEA malaria treatment market is segmented into prescription medications, vaccines, diagnostic tests, and others. The diagnostic tests segment held the largest market share in 2022. The prescription medications segment is further categorized into chloroquine phosphate, artemisinin-based combination therapies (ACTs), atovaquone-proguanil, quinine sulfate (qualaquin) with doxycycline, primaquine phosphate, and others.

Based on drug type, the MEA malaria treatment market is bifurcated into branded and generic. The generic segment held a larger market share in 2022.

Based on route of administration, the MEA malaria treatment market is bifurcated into oral and parenteral & intravenous. The oral segment held a larger market share in 2022.

Based on distribution channel, the MEA malaria treatment market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. The direct tender segment held the largest market share in 2022.

Based on end user, the MEA malaria treatment market is segmented into hospitals, specialty clinics, homecare, and others. The specialty clinics segment held the largest market share in 2022.

Based on country, the MEA malaria treatment market has been categorized into Saudi Arabia, South Africa, the UAE, Nigeria, The Democratic Republic of Congo, the United Republic of Tanzania, Mozambique, Uganda, Ghana, Burkina Faso, Kenya, Zambia, and the Rest of MEA. Our regional analysis states that Saudi Arabia dominated the market in 2022.

AdvaCare Pharma USA LLC, Cipla Ltd, GSK Plc, Lupin Ltd, Novartis AG, Sanofi SA, Sun Pharmaceutical Industries Ltd, Viatris Inc, and Zydus Healthcare Ltd are among the leading companies operating in the MEA malaria treatment market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the MEA malaria treatment market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the MEA malaria treatment market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth MEA market trends and outlook coupled with the factors driving the malaria treatment market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution